Nafamostat mesilate inhibits linezolid metabolism via its antioxidant effects

Naohide Kuriyama, Kana Matsumoto, Kunihiko Morita, Yasuyo Shimomura, Yoshitaka Hara, Daisuke Hasegawa, Tomoyuki Nakamura, Chizuru Yamashita, Yu Kato, Hidefumi Komura, Osamu Nishida

Research output: Contribution to journalArticlepeer-review

Abstract

Patients who undergo renal replacement therapy often exhibit a high plasma linezolid concentration. Linezolid is metabolized via oxidation. Nafamostat mesilate has antioxidant effects and is frequently used as an anticoagulant during renal replacement therapy. We aimed to investigate the effect of nafamostat mesilate on plasma linezolid concentration. We examined whether the co-administration of linezolid and nafamostat had any effect on plasma linezolid concentration. Mice were randomly allocated to two groups (n = 18/group): linezolid (100 mg kg−1, subcutaneous injection) + nafamostat (30 mg kg−1, intraperitoneal injection) and linezolid + saline. At 5 hours, the linezolid concentration was significantly higher in the linezolid + nafamostat co-administration group than that in the linezolid + saline group (20.6 ± 9.8 vs 3.6 ± 1.2 μg/mL, respectively P <.001). The antioxidant effects of nafamostat may inhibit linezolid metabolism, resulting in the adverse event of high linezolid concentration if both are administered concurrently during renal replacement therapy.

Original languageEnglish
Pages (from-to)499-502
Number of pages4
JournalTherapeutic Apheresis and Dialysis
Volume24
Issue number5
DOIs
StatePublished - 1 Oct 2020
Externally publishedYes

Keywords

  • linezolid
  • multidrug resistance
  • nafamostat
  • renal replacement therapy
  • serine proteinase inhibitor

Fingerprint

Dive into the research topics of 'Nafamostat mesilate inhibits linezolid metabolism via its antioxidant effects'. Together they form a unique fingerprint.

Cite this